Haemonetics Corporation

07/30/2024 | Press release | Distributed by Public on 07/30/2024 14:24

Amendment to Current Report Form 8 K/A

hae-20240725
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 25, 2024
HAEMONETICS CORPORATION
(Exact name of registrant as specified in its charter)
Massachusetts 001-14041 04-2882273
(State or other jurisdiction
of incorporation)
(Commission File Number)
(I.R.S. Employer
Identification No.)
125 Summer Street
Boston, MA02110
(Address of principal executive offices, including zip code)
Registrant's telephone number, including area code: 781-848-7100
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common stock, $.01 par value per share HAE New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging Growth Company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Explanatory Note
Haemonetics Corporation (the "Company") filed a Current Report on Form 8-K on July 25, 2024 (the "Original Report"). This amendment to the Original Report (this "Amendment") amends and restates Item 5.07 of the Original Report in its entirety to correct a clerical error when referencing the Company's current fiscal year in the description of proposal 3. This Amendment does not modify or update any other information set forth in the Original Report.
Item 5.07 Submission of Matters to a Vote of Security Holders.
The Company's 2024 Annual Meeting of Shareholders was held on Thursday, July 25, 2024. Of the 50,953,098 shares outstanding and entitled to vote at the meeting, 48,912,250 shares were represented at the meeting, constituting a quorum of 95.99%.
The results of the votes for each proposal considered at the meeting are set forth below:
1. The shareholders elected each of Christopher A. Simon, Robert E. Abernathy, Diane M. Bryant, Michael J. Coyle, Charles J. Dockendorff, Lloyd E. Johnson, Mark W. Kroll, Claire Pomeroy and Ellen M. Zane as directors for one-year terms expiring in 2025 based upon the following votes:
Nominees For Withhold Broker Non-Votes
Christopher A. Simon 47,563,311 269,386 1,079,553
Robert E. Abernathy 47,233,098 599,599 1,079,553
Diane M. Bryant 47,637,507 195,190 1,079,553
Michael J. Coyle 47,492,931 339,766 1,079,553
Charles J. Dockendorff 46,789,643 1,043,054 1,079,553
Lloyd E. Johnson 47,243,880 588,817 1,079,553
Mark W. Kroll 46,938,807 893,890 1,079,553
Claire Pomeroy 47,553,094 279,603 1,079,553
Ellen M. Zane 47,122,780 709,917 1,079,553
2. The shareholders approved, on an advisory basis, the compensation of the Company's named executive officers based upon the following votes:
For Against Abstain Broker Non-Votes
46,230,466 1,460,004 142,227 1,079,553
3. The shareholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending March 29, 2025 based upon the following votes:
For Against Abstain
47,738,769 1,049,682 123,799
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
HAEMONETICS CORPORATION
July 30, 2024 By: /s/ Christopher A. Simon
Name: Christopher A. Simon
Title: President and Chief Executive Officer